KR20150129718A - Ｇｒｅｍ 1에 대한 인간 항체 - Google Patents

Ｇｒｅｍ 1에 대한 인간 항체 Download PDF

Info

Publication number
KR20150129718A
KR20150129718A KR1020157024673A KR20157024673A KR20150129718A KR 20150129718 A KR20150129718 A KR 20150129718A KR 1020157024673 A KR1020157024673 A KR 1020157024673A KR 20157024673 A KR20157024673 A KR 20157024673A KR 20150129718 A KR20150129718 A KR 20150129718A
Authority
KR
South Korea
Prior art keywords
antibody
grem1
antigen
seq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157024673A
Other languages
English (en)
Korean (ko)
Inventor
아리스 에코노미데스
빈센트 제이. 아이던
로리 씨. 모턴
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20150129718A publication Critical patent/KR20150129718A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020157024673A 2013-03-14 2014-03-07 Ｇｒｅｍ 1에 대한 인간 항체 Withdrawn KR20150129718A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361782874P 2013-03-14 2013-03-14
US61/782,874 2013-03-14
US201361883218P 2013-09-27 2013-09-27
US61/883,218 2013-09-27
PCT/US2014/021471 WO2014159010A1 (en) 2013-03-14 2014-03-07 Human antibodies to grem 1

Publications (1)

Publication Number Publication Date
KR20150129718A true KR20150129718A (ko) 2015-11-20

Family

ID=50390267

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024673A Withdrawn KR20150129718A (ko) 2013-03-14 2014-03-07 Ｇｒｅｍ 1에 대한 인간 항체

Country Status (18)

Country Link
US (3) US10377817B2 (cg-RX-API-DMAC10.html)
EP (1) EP2970448B1 (cg-RX-API-DMAC10.html)
JP (2) JP6581075B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150129718A (cg-RX-API-DMAC10.html)
CN (1) CN105189548A (cg-RX-API-DMAC10.html)
AU (1) AU2014241442B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015021979A2 (cg-RX-API-DMAC10.html)
CA (1) CA2904644C (cg-RX-API-DMAC10.html)
CL (1) CL2015002603A1 (cg-RX-API-DMAC10.html)
EA (1) EA201591762A1 (cg-RX-API-DMAC10.html)
ES (1) ES2898620T3 (cg-RX-API-DMAC10.html)
HK (1) HK1220469A1 (cg-RX-API-DMAC10.html)
IL (1) IL240769A0 (cg-RX-API-DMAC10.html)
MX (1) MX369574B (cg-RX-API-DMAC10.html)
PH (1) PH12015501865A1 (cg-RX-API-DMAC10.html)
SG (2) SG11201506459PA (cg-RX-API-DMAC10.html)
WO (1) WO2014159010A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201506113B (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013137686A1 (ko) * 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
BR112015021979A2 (pt) 2013-03-14 2017-08-29 Regeneron Pharma Anticorpos humanos para grem1
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
IL263481B2 (en) * 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
CN106399316B (zh) * 2016-08-26 2019-03-01 西安交通大学第一附属医院 用于识别Gremlin-1的核酸适配子及其应用
CN109641954A (zh) * 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
MA49273A (fr) 2017-03-22 2020-02-05 Bluefin Biomedicine Inc Anticorps anti-tmeff1 et conjugués anticorps-médicament
US12161694B2 (en) * 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
AU2019289176B2 (en) * 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
AU2020385991A1 (en) 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
EP4232475A1 (en) * 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
AU2022207030A1 (en) * 2021-01-18 2023-08-24 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
KR20230156936A (ko) * 2021-03-11 2023-11-15 상하이 지아오통 대학 그렘린1 길항제를 사용하여 질환을 치료하는 방법
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
AU2023258146A1 (en) * 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑
CN115786495A (zh) * 2022-10-24 2023-03-14 杭州市第七人民医院 检测基因表达量的试剂在制备尼古丁加重的糖尿病肾病的筛查试剂盒中的用途
KR20250169623A (ko) * 2023-04-13 2025-12-03 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 암 치료를 위한 grem1 길항제를 수반하는 조합 요법
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
WO1998033918A1 (en) 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1966725A (zh) 2001-10-31 2007-05-23 爱尔康公司 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
EP1738767A1 (en) 2001-10-31 2007-01-03 Alcon, Inc. Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20090041747A1 (en) 2005-02-24 2009-02-12 Novo Nordisk Health Care Ag Compounds for Stabilizing Factor VII Polypeptide Formulations
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2013137686A1 (ko) 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
BR112015021979A2 (pt) 2013-03-14 2017-08-29 Regeneron Pharma Anticorpos humanos para grem1

Also Published As

Publication number Publication date
EA201591762A1 (ru) 2015-12-30
CL2015002603A1 (es) 2016-03-04
CA2904644C (en) 2022-09-20
MX369574B (es) 2019-11-13
WO2014159010A1 (en) 2014-10-02
BR112015021979A2 (pt) 2017-08-29
CN105189548A (zh) 2015-12-23
PH12015501865A1 (en) 2015-12-07
ES2898620T3 (es) 2022-03-08
JP2016519650A (ja) 2016-07-07
US20200157194A1 (en) 2020-05-21
JP2019151654A (ja) 2019-09-12
EP2970448B1 (en) 2021-11-03
US10377817B2 (en) 2019-08-13
IL240769A0 (en) 2015-10-29
SG11201506459PA (en) 2015-09-29
AU2014241442B2 (en) 2018-11-15
US20160024195A1 (en) 2016-01-28
US20230192831A1 (en) 2023-06-22
EP2970448A1 (en) 2016-01-20
US11634480B2 (en) 2023-04-25
CA2904644A1 (en) 2014-10-02
JP6581075B2 (ja) 2019-09-25
ZA201506113B (en) 2016-07-27
MX2015011616A (es) 2015-12-17
AU2014241442A1 (en) 2015-10-15
HK1220469A1 (zh) 2017-05-05
SG10201707518YA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
US20230192831A1 (en) Human Antibodies to GREM1
AU2017245479C1 (en) Anti-PDGFR-beta antibodies and uses thereof
KR102534895B1 (ko) 항-c5 항체 및 이의 용도
AU2016307430B2 (en) Anti-ANGPTL8 antibodies and uses thereof
CN114057869B (zh) 针对中东呼吸综合征-冠状病毒刺突蛋白的人抗体
KR101952786B1 (ko) 글루카곤 수용체에 대한 인간 항체
KR102440044B1 (ko) 항-액티빈 a 항체 및 그의 용도
DK2475684T3 (en) HUMAN HIGH-EFFICIENCY ANTIBODIES AGAINST HUMAN PROTEASE-ACTIVATED RECEPTOR-2
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
KR101859911B1 (ko) 사람 ｇｄｆ８에 대한 항체
AU2013305863B2 (en) Human antibodies to GFRalpha3 and methods of use thereof
AU2018204895A1 (en) Anti-EGFR antibodies and uses thereof
KR20130132842A (ko) 인간 tnf-유사 리간드 1a(tl1a)에 대한 인간 항체
KR20140125363A (ko) 항-ａｓｉｃ1 항체 및 그 용도
PH12014501730B1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
KR20190078650A (ko) 항-angptl8 항체를 사용하는 비만의 치료 방법
CN110167965A (zh) 拮抗瘦素受体的抗原结合蛋白
KR20210022650A (ko) 항-인자 XII/XIIa 항체 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150909

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid